News

Doctor Honoris Causa title conferred on Prof. Federica Sallusto

Bellinzona, Nov. 17, 2022 – During the Dies Academicus, the University of Fribourg conferred to Prof. Federica Sallusto the title Doctor honoris causa (Dr. h. c.) for her excellence in scientific and ...

Secretory IgA promotes gut fitness

Secretory Immunoglobulin A (SIgA) is the antibody produced within mucosal membranes and is the most abundant antibody type synthesized in our body. In the intestine, SIgA possesses two antithetic func...

Melanoma metastasis: new IRB study

Melanoma is the most lethal skin cancer, and its incidence, though low, has steadily increased over the last few years. During melanoma progression, tumor cells spread across the body via the lymphati...

Opening for Group Leader position at the IRB

The Institute for Research in Biomedicine (IRB) officially opened an international call for the recruitment of a new group leader (deadline December 1, 2022). We seek an outstanding scientist to comp...

Bios+: Open Day under the banner of Science and curiosity

Recent years have generated considerable demand for information and interaction between Science and society. In this sense, the open day organized in the new Bios+ building in Bellinzona by IRB, IOR...

A new research group at the IOR

On 1 September 2022, a new research group led by Dr Arianna Baggiolini began its activities at the Institute of Oncology Research (IOR) in Bellinzona. This makes six groups in the research programme d...

Also dogs develop malignant lymphoma

A study conducted by scientists at the Institute of Oncology Research (IOR, affiliated with USI and a member of Bios+) in collaboration with researchers specialized in veterinary oncology at the Unive...

Bios+: Nearly 1’000 visitors to the Bellinzona Research Institutes' Open day

On Saturday, May 14, the Institute for Research in Biomedicine (IRB), the Institute of Oncology Research (IOR) and the Laboratories for Translational Research of the EOC opened the doors of the new Bi...

Lymphomas: new model developed at the IOR against drug resistance

The Lymphoma Genomics group, directed by Prof. Francesco Bertoni at the Institute of Oncology Research (IOR, affiliated to USI and member of Bios+), identified a new mechanism behind the resistance to...

Breakthroughs at IOR in the research for anti-metastatic therapies

The Molecular Oncology research group lead by  Prof. Andrea Alimonti at the Istitute of Oncology Research (IOR, affiliated to USI and member of Bios+) has identified, through the use of bioinform...

Francesco Bertoni has been elected as President of the Lymphoma Project Group of Swiss Group for Clinical Cancer Research

Lymphomas have always been a main focus for the Institute of Oncology Research (IOR) and the Oncology Institute of Southern Switzerland (IOSI - EOC). After many years dedicated to lymphoma research, B...

The Swiss Institute of Bioinformatics renews Luciano Cascione's mandate as SIB Group leader at the IOR

The SIB Swiss Institute of Bioinformatics is an internationally recognized non-profit organization dedicated to biological and biomedical data science. It is present in the main academic institutions ...

IOR publication on cancer among the "Top 10" in Europe

The EACR European Association for Cancer Research has included a publication of the Institute of Oncology Research (IOR, affiliated to USI) in its "Top 10 Cancer Research Publications", which ranks th...

Pfizer Research Prize in Oncology for research performed at IOR

The awards for the 31st Pfizer Prize for Research were given on Thursday, February 10th, in Zurich. Among the winners of the Oncology category were Ilaria Guccini and Ajinkya Revandka, former research...

IOR and IOSI gold medal in lymphomas

The New England Journal of Medicine (NEJM), the world's leading medical journal, has entrusted the lymphoma group of the Institute of Oncological Research (IOR, affiliated to USI and member of Bios+) ...

IOR researchers develops a novel method to track precisely prostate cancer progression

In the fight against tumours, how the key driver mutations related to disease progression and metastatic spread regulate gene expression to promote ultimately tumor progression and cancer cell adaptat...

VIDEO RECORDING of the new building inauguration (27.11.2021)

Watch the recap video:   Watch the complete video recording: ...

Roger Geiger selected to the EMBO Young Investigator programme

The European Molecular Biology Organisation (EMBO) has selected Roger Geiger, group leader at the Institute for Research in Biomedicine (IRB, affiliated to USI Università della Svizzera...

Interplay of Dna2 and RPA in DNA metabolism, a Nature Communications paper

DNA end resection is required for accurate processing of broken DNA. In a paper published in Nature Communications, IRB researchers Acharya, Cejka and colleagues investigated the interplay o...

Krebsliga awards the Robert Wenner prize to Davide Rossi at IOR

Swiss Cancer League - Krebsliga - has awarded the 2019 Robert Wenner Prize for young cancer researchers to Davide Rossi, Group leader at the Institute of Oncology Research (IOR, affiliated to Universi...

Inaugurata la nuova sede degli Istituti di ricerca scientifica IRB, IOR e EOC

Oltre 250 le persone presenti alla cerimonia del nuovo stabile di proprietà della Fondazione IRB Si è tenuta oggi la cerimonia d’inaugurazione ufficiale della nuova sede degli Istituti di ricerca s...

A "jubilee grant" of the Helmut Horten Foundation awarded for research against lymphoma

On October 22, 2021, the Helmut Horten Foundation celebrated its 50th anniversary with a ceremony held at ETH Zurich. On this occasion, researchersDavide Rossiat the Institute of Oncology Research (IO...

Intestinal bacteria mechanism discovered at the IOR that could improve prostate cancer therapy

Scientists at the Institute of Oncology Research (IOR, affiliated to USI) and The Institute of Cancer Research, London, in collaboration with researchers from the University of Padova, have made a ver...

Engineered bacteria for cancer immunotherapy

A Nature paper by theSystems Immunologygroup, headed byRoger Geiger, at the Institute for Research in Biomedicine (IRB, affiliated to USI). This study describes an innovative strategy to improve the ...

New SNSF grants awarded to three IRB researchers

The Swiss National Science Foundation (SNSF) has recently awarded three group leaders at the Institute for Research in Biomedicine (IRB, affiliated to USI): Silvia Monticelli, Santiago González and Pe...

First peptide inhibitor of the CXCL12/HMGB1 heterocomplex identified

During inflammatory reactions, the production and release of chemotactic factors guide the recruitment of selective leukocyte subpopulations. The chemokine CXCL12 and the alarmin HMGB1, both released ...

IRB ready for clinical testing of second generation antibody against COVID-19

Following the development of a second-generation antibody against the novel coronavirus (SARS-CoV-2) and its variants, the Institute for Research in Biomedicine (IRB, affiliated to USI) is now mo...

IOR research project receives important funding from the United States

The American Society of Hematology (ASH) – the world’s leading association in the field of hematology – has awarded Dr. Adalgisa Condoluci, a researcher at the IOR, with the “ASH Global Research Award...

A Single Vaccine Against Coronaviruses is a step closer

The spillovers of β-coronaviruses in humans and the emergence of SARS-CoV-2 variants highlight the need for broad coronavirus countermeasures. A study co-authored by Dr. Jun Siong Low, Postdoc at t...

A molecular switch turns on the unfavorable evolution of prostate tumors

Researchers of the Prostate Cancer Biology group, directed by Giuseppina Carbone, M.D.  of the Institute of Oncology Research (IOR) discovered an unexpected mechanism that drives the evolution of...

Liver disease associated to alpha1-antitrypsin deficiency: a paper by Molinari’s lab

About 10% of the children with alpha1-antitrypsin deficiency must undergo liver transplantation. Their hepatocytes fail to properly degrade polymers of mutant alpha1-antitrypsin (ATZ), whose accumulat...

LICTOR, a new powerful tool to prevent systemic light-chain amyloidosis

Systemic light-chain amyloidosis (AL) is the most common form of a group of diseases associated with protein misfolding, leading to deposition of insoluble structures in different organs. Due to the...

New paper from the González’s lab

A paper from the González’s lab studies how to modify the innate immune response to improve the adaptive immunity against a potential HIV vaccine. To study this mechanism, we have employed the revolu...

A single new weapon against multiple viruses transmitted by ticks

 The bite of a tick can transmit Tick-Borne Encephalitis Virus (TBEV), which can cause brain infection, hospitalisation and long term neurologic problems. TBEV is only one among half a dozen vir...

Prestigious professorship awarded at the Institute of Oncology Research in Bellinzona

Stiftung Experimentelle Biomedizin has awarded Dr Arianna Calcinotto, Group Leader at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana) the Peter Hans...

The IRB joins international network for the study of emerging infectious diseases

The IRB announces it has joined the United World Antiviral Research Network (UWARN), the organisation that brings together researchers from leading institutions in several countries around the globe t...

IOR study reveals how breast cancer therapy may be effective against COVID-19

A study conducted by the Institute of Oncology Research (IOR, affiliated to USI) based on data obtained from the Veneto Tumor Registry (Italy) has observed a lower risk of developing the coronavirus d...

Why Specific Genetic Alterations Matter in Prostate Cancer

A given substance may be fundamental for life or may serve as a poison. All depends on the specific dose. At first glance, this somewhat paradoxical principle in medicine was first coined by the Swiss...

Circulating plasma extracellular vesicles give new insights for monitoring and managing disease progression in prostate cancer patients

The study by Albino et al. is published in Communications Biology and is available at https://doi.org/10.1038/s42003-020-01642-5. The work is a collaborative effort involving many rese...

Second generation antibody protects from SARS-CoV-2, its variant and prevents it from mutating to resist therapy

The Institute for Research in Biomedicine (IRB; Bellinzona, Switzerland), affiliated to the Università della Svizzera italiana (USI) developed a second-generation ‘double antibody’ that protects from ...

New Ebolavirus treatment sees the light thanks to basic research performed in Ticino

While populations around the world are being vaccinated against SARS-CoV-2, the U.S. Food and Drug Administration has announced the approval of a treatment against another well-known virus, much les...

Congratulations to Prof. Alimonti and his Molecular Oncology team on receiving the Prostate Cancer Foundation Challenge Award

Prof. Alimonti from the Institute of Oncology Research (IOR) in Bellinzona, Switzerland and Prof. De Bono from the Institute of Cancer Research (ICR) in London, United Kingdom, just received this pres...

IOR researchers suggest that androgen-deprivation treatments for prostate cancer could protect men from COVID-19

The so-called “androgen-deprivation” treatments used in prostate cancer therapy may have a protective effect against COVID-19. A study conducted by the Istitute of Oncology Research (IOR, affiliated ...

Press review